# Efficacy and Safety Study of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease

> **NCT00573469** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 75 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** D9421-C, 9mg
- **DRUG:** D9421-C, 15mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00573469
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2012-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00573469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00573469, "Efficacy and Safety Study of D9421-C 9 mg and 15 mg Versus Placebo in Japanese Patients With Active Crohn's Disease". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00573469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*